Compare Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily 20 Year Treasury Bull 3X Shares vs Zimmer Biomet Holdings Inc — how do they compare? Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.73 (market cap $2.06B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 8.2× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TMF | ZBH | |
|---|---|---|
Market Cap | $2.06B | $16.95B |
Volume | 10,528,006 | 2,505,240 |
Sector | Fixed Income | Health |
52-Week High | $44.14 | $103.98 |
52-Week Low | $25.19 | $79.58 |
Typical Hold Time | 28 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMF (Direxion Daily 20+ Year Treasury Bull 3X ETF) trades at $25.23, down 0.51% with elevated trading volume of 5.2 million shares. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oversold RSI readings suggest potential for near-term bounce. The ETF saw increased investor interest amid bond market volatility.
As a leveraged Treasury ETF, TMF offers amplified exposure to long-term bond performance but carries significant volatility risk. Current oversold conditions may present tactical opportunities, though the bearish technical structure and interest rate sensitivity require careful risk management for investors seeking directional bond exposure.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
